Market Closed -
Nasdaq
04:30:01 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
3.06
USD
|
-0.33%
|
|
-1.29%
|
-4.97%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
198.4
|
146.5
|
218.6
|
131.1
|
227.6
|
216.7
|
-
|
-
|
Enterprise Value (EV)
1 |
198.4
|
146.5
|
218.6
|
131.1
|
227.6
|
216.7
|
216.7
|
216.7
|
P/E ratio
|
-2.69
x
|
-1.66
x
|
1.82
x
|
-2.42
x
|
-4.35
x
|
-4.11
x
|
-8.46
x
|
-4.92
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
11.6
x
|
1.05
x
|
87.2
x
|
581
x
|
19
x
|
4.96
x
|
7.17
x
|
EV / Revenue
|
-
|
11.6
x
|
1.05
x
|
87.2
x
|
581
x
|
19
x
|
4.96
x
|
7.17
x
|
EV / EBITDA
|
-
|
-
|
1.76
x
|
-2.38
x
|
-3.95
x
|
-4.22
x
|
-277
x
|
-
|
EV / FCF
|
-3.88
x
|
-
|
-
|
-
|
-
|
-2.7
x
|
-2.91
x
|
-2.63
x
|
FCF Yield
|
-25.8%
|
-
|
-
|
-
|
-
|
-37.1%
|
-34.3%
|
-38.1%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
47,816
|
63,435
|
68,092
|
70,467
|
70,681
|
70,811
|
-
|
-
|
Reference price
2 |
4.150
|
2.310
|
3.210
|
1.860
|
3.220
|
3.060
|
3.060
|
3.060
|
Announcement Date
|
3/11/20
|
3/15/21
|
3/15/22
|
3/13/23
|
3/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
12.62
|
208.4
|
1.503
|
0.3917
|
11.42
|
43.7
|
30.2
|
EBITDA
1 |
-
|
-
|
124.4
|
-55.04
|
-57.68
|
-51.39
|
-0.7813
|
-
|
EBIT
1 |
-61.41
|
-81.43
|
149.2
|
-55.55
|
-59.28
|
-55.44
|
-26.77
|
-49.03
|
Operating Margin
|
-
|
-645.4%
|
71.58%
|
-3,696.43%
|
-15,134.4%
|
-485.43%
|
-61.25%
|
-162.33%
|
Earnings before Tax (EBT)
1 |
-60.46
|
-81.04
|
124.2
|
-54.17
|
-52.34
|
-51.43
|
-23.76
|
-45.89
|
Net income
1 |
-60.46
|
-81.04
|
122.8
|
-54.17
|
-52.34
|
-54.64
|
-30.13
|
-55.13
|
Net margin
|
-
|
-642.26%
|
58.95%
|
-3,604.66%
|
-13,362%
|
-478.45%
|
-68.95%
|
-182.54%
|
EPS
2 |
-1.540
|
-1.390
|
1.760
|
-0.7700
|
-0.7400
|
-0.7444
|
-0.3618
|
-0.6225
|
Free Cash Flow
1 |
-51.15
|
-
|
-
|
-
|
-
|
-80.32
|
-74.35
|
-82.45
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-703.23%
|
-170.13%
|
-272.99%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/15/21
|
3/15/22
|
3/13/23
|
3/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
1.445
|
-
|
0.0111
|
0.0463
|
0.0662
|
0.075
|
0.109
|
0.1416
|
0.0521
|
0.0584
|
0.0584
|
14.49
|
0.05
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-17.79
|
-12.41
|
-12.69
|
-12.99
|
-
|
-
|
EBIT
1 |
-11.68
|
-11.65
|
-14.29
|
-14.3
|
-12.8
|
-12.17
|
-14.89
|
-14.17
|
-12.03
|
-18.19
|
-16.81
|
-17.3
|
-18.11
|
-1.616
|
-17.56
|
Operating Margin
|
-
|
-
|
-988.59%
|
-
|
-115,350.09%
|
-26,302.29%
|
-22,509.52%
|
-18,895.97%
|
-11,038.66%
|
-12,848.51%
|
-32,246.41%
|
-29,631.43%
|
-31,022.61%
|
-11.15%
|
-35,122%
|
Earnings before Tax (EBT)
1 |
-11.68
|
-26.35
|
-16.06
|
-14.59
|
-11.97
|
-11.5
|
-13.36
|
-12.41
|
-11.25
|
-15.32
|
-15.48
|
-16
|
-16.81
|
-0.3587
|
-16.23
|
Net income
1 |
-11.38
|
-26
|
-16.11
|
-14.59
|
-11.97
|
-11.5
|
-13.36
|
-12.41
|
-11.25
|
-15.32
|
-15.96
|
-16.56
|
-17.33
|
-5.152
|
-16.23
|
Net margin
|
-
|
-
|
-1,114.46%
|
-
|
-107,817.75%
|
-24,858.64%
|
-20,187.74%
|
-16,544.44%
|
-10,326.14%
|
-10,823.71%
|
-30,629.8%
|
-28,369.73%
|
-29,691.88%
|
-35.55%
|
-32,456%
|
EPS
2 |
-0.1700
|
-0.3800
|
-0.2300
|
-0.2100
|
-0.1700
|
-0.1600
|
-0.1900
|
-0.1800
|
-0.1600
|
-0.2200
|
-0.2196
|
-0.2267
|
-0.2305
|
-0.0588
|
-0.2167
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/15/22
|
5/10/22
|
8/9/22
|
11/8/22
|
3/13/23
|
5/5/23
|
8/4/23
|
11/3/23
|
3/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-51.1
|
-
|
-
|
-
|
-
|
-80.3
|
-74.4
|
-82.4
|
ROE (net income / shareholders' equity)
|
-
|
-
|
110%
|
-34.7%
|
-47.6%
|
-52.4%
|
-1.3%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.06
|
-
|
-
|
-
|
0.14
|
0.02
|
0.41
|
0.59
|
Capex / Sales
|
-
|
-
|
-
|
-
|
35.09%
|
0.18%
|
0.94%
|
1.95%
|
Announcement Date
|
3/11/20
|
3/15/21
|
3/15/22
|
3/13/23
|
3/8/24
|
-
|
-
|
-
|
Last Close Price
3.06
USD Average target price
7.625
USD Spread / Average Target +149.18% Consensus |
1st Jan change
|
Capi.
|
---|
| -4.97% | 217M | | +8.96% | 105B | | -1.43% | 104B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +38.61% | 12.63B | | +313.59% | 8.49B |
Bio Therapeutic Drugs
|